Effects of primary percutaneous coronary intervention combined with tirofiban therapy in patients with acute ST-segmentmyocardial infarction
JIN Wei-dong
LIU Yan-bin
WANG Peng-fei
Abstract：Objective To study the effects of primary percutaneous coronary intervention combined with tirofiban therapy on myocardial perfusion and clinical outcomes in patients with acute ST-segment myocardial infarction(STEMI) and to observe the effect of tirofiban hydrochlotide on serum hs2CRP level. Methods Ninty-six consecutive patients with acute STEMI were randomly allocated to either primary PCI combined with tirofiban therapy or primary PCI treatment alone. Baseline characteristics, left ventricular ejection faction, majoradverse cardiac events (MACE) were cospared. Serum hs-CRP leves were determinded by the latex enhanced immunoturbidimetric method. Results The baseline clinical characteristics were comparable between the two groups. The TIMI grade 3 flow was similar between the tirofiban and control groups, but the resolution of sum of ST-segment elevation, peak-value of CK-MB, EF, LVEDD, LVESD, and the MACE rates at 60 days in tirofiban group were better than those in the control group. The level of hs-CRP had no significant difference between two groups before treatment, but after treatment, serum hs-CRP was significantly decreased by tirofiban hydrochloride treatment compared to the control group.Conclusions Adjunctive therapy with tirofiban for patients with acute STEMI who undergo primary PCI can improve reperfusion in the infarction area and clinical outcomes at 60 days. Tirofiban hydrochloride can delay the process of ACS via inhibiting inflammation.
Keywords：Myocardial infarctionMyocardial reperfusionTirofibanC-reactive protein
Publication Date：2011-01-01
Online Publishing Date：2026-09-14(First online date of this platform, not the publication date of the document)